Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells

International Journal of Cancer

Volumn 123, Issue 10, 2008, Pages 2294-2302

  Floryk, Daniel ^a,b   Thompson, Timothy C ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AVN944; Cell death; Differentiation; IMPDH; Prostate cancer; TRAIL

Indexed keywords

ANDROGEN; AVN 944; CASPASE; INOSINATE DEHYDROGENASE INHIBITOR; KERATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN; PROTEIN BAX; PROTEIN BOK; PROTEIN DERIVATIVE; PROTEIN NOXA; PROTEIN P53; PURINE NUCLEOTIDE; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CARBAMIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; ENZYME INHIBITOR; INOSINATE DEHYDROGENASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRUCTURE; CONTROLLED STUDY; DRUG DOSE INCREASE; ENZYME INDUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MIG 6 GENE; NDRG1 PROTEIN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TUMOR SUPPRESSOR GENE; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; APOPTOSIS; CARBAMATES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMP DEHYDROGENASE; MALE; PHENYLUREA COMPOUNDS; PROSTATIC NEOPLASMS;

EID: 53449087581     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23788     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 1990;265:5292-5.
3. Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 1975;256:331-3.
4. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res 1983;43:3466-92.
5. Allison AC, Hovi T, Watts RW, Webster AD. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977;48:207-24.
6. Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ, Jr, Liu JO. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 2006;49:2677-80.
7. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005;80:S181-S190.
8. Yalowitz JA, Jayaram HN. Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res 2000;20:2329-38.
9. Sokoloski JA, Blair OC, Sartorelli AC. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5′-phosphate dehydrogenase. Cancer Res 1986;46:2314-19.
10. Goldstein BM, Leary JF, Farley BA, Marquez VE, Levy PC, Rowley PT. Induction of HL60 cell differentiation by tiazofurin and its analogues: characterization and efficacy. Blood 1991;78:593-8.
11. Olah E, Natsumeda Y, Ikegami T, Kote Z, Horanyi M, Szelenyi J, Paulik E, Kremmer T, Hollan SR, Sugar J. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells. Proc Natl Acad Sci USA 1988;85:6533-7.
12. Kiguchi K, Collart FR, Henning-Chubb C, Huberman E. Induction of cell differentiation in melanoma cells by inhibitors of IMP dehydrogenase: altered patterns of IMP dehydrogenase expression and activity. Cell Growth Differ 1990;1:259-70.
13. Khanna N, Jayaram HN, Singh N. Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells. Life Sci 2004;75:179-90.
14. Floryk D, Tollaksen SL, Giometti CS, Huberman E. Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5′-monophosphate dehydrogenase. Cancer Res 2004;64:9049-56.
15. Floryk D, Huberman E. Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145. Cancer Lett 2006;231:20-9.
16. Tricot GJ, Jayaram HN, Lapis E, Natsumeda Y, Nichols CR, Knee-bone P, Heerema N, Weber G, Hoffman R. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity. Cancer Res 1989;49:3696-701.
17. Jain J, Ma J, Furey B, Recher C, Demur C, Poondru S, Zhang J, Li S, Firestone B, Olson K, Murphy M, Taylor J, et al. The IMPDH inhibitor VX-944 demonstrates in vivo efficacy in an aggressive leukemia model. ASH Annual Meeting Abstracts 2004;104:2530.
18. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, Le Gouill S, Shiraishi N, Yasui H, Roccaro AM, Tai YZ, Chauhan D, et al. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene 2005;24:5888-96.
19. Jain J, Almquist S, Hoover R, Shlyakhter D, Ford P, Markland W, van Drie J, Rasmussen R, Weber P, Dauffenbach L, Kerfoot C, Mosher R. VX-944: an inosine monophosphate dehydrogenase inhibitor with unique anti-cancer activity. 18th EQRTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" Geneva, Switzerland, 2004.
20. Floryk D, Huberman E. Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factorkappaB activity. Cancer Res 2005;65:11588-96.
21. Floryk D, Houstek J. Tetramethyl rhodamine methyl ester (TMRM) is suitable for cytofluorometric measurements of mitochondrial membrane potential in cells treated with digitonin. Biosci Rep 1999;19:27-34.
22. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003;31:e154.
23. Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem 2005;280:31230-9.
24. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12:1543-68.
25. Sheikh MS, Huang Y. Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets 2004;4:97-104.
26. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004;16:139-44.
27. Van Ophoven A, Ng CP, Patel B, Bonavida B, Belldegrun A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. Prostate Cancer Prostatic Dis 1999;2:227-33.
28. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001;6:191-7.
29. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003;63:4713-23.
30. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005;62:165-86.
31. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. Death receptor-induced cell death in prostate cancer. J Cell Biochem 2004;91:70-99.
32. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001;61:759-63.
33. Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 2002;53:286-99.
34. Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 2002;1:520-7.
35. Jeon KI, Rih JK, Kim HJ, Lee YJ, Cho CH, Goldberg ID, Rosen EM, Bae I. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett 2003;544:246-51.
36. Wu XX, Ogawa O, Kakehi Y, Mizutani Y, Nishiyama H, Kamoto T, Megumi Y, Ito N, Kinoshita H, Isogawa Y, Terachi T. TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 2004;67:365-83.
37. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, Gautam SC. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2003;2:95-103.
38. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005;4:443-9.
39. Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res 2005;65:6364-70.
40. Pankiewicz KW. Novel nicotinamide adenine dinucleotide analogues as potential anticancer agents: quest for specific inhibition of inosine monophosphate dehydrogenase. Pharmacol Ther 1997;76:89-100.
41. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
42. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 1994;9:1791-8.
43. Yakovlev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 2004;279:28367-74.
44. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
45. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003;23:9389-404.